Series A and Series A-1 Preferred Stock Purchase Agreement



 Exhibit 10.16 

 
 INCAPSULA, INC. 

SERIES A AND SERIES A-1 PREFERRED 
 STOCK PURCHASE AGREEMENT 
 March 9, 2010 







 TABLE OF CONTENTS 

 

					
	  	  	Page	 
		
	 1.      Purchase and Sale of Stock
	  	 	1	  
	 1.1        Sale and Issuance of Series A and Series A-l Preferred
Stock
	  	 	1	  
	 1.2        Closing
	  	 	2	  
	 1.3        Subsequent Sale of Series A-l Preferred Stock
	  	 	2	  
		
	 2.      Representations and Warranties of the Company
	  	 	3	  
	 2.1        Organization, Good Standing and Qualification
	  	 	3	  
	 2.2        Capitalization and Voting Rights
	  	 	3	  
	 2.3        Subsidiaries
	  	 	4	  
	 2.4        Authorization
	  	 	4	  
	 2.5        Valid Issuance of Preferred and Common Stock
	  	 	5	  
	 2.6        Governmental Consents
	  	 	5	  
	 2.7        Offering
	  	 	5	  
	 2.8        Litigation
	  	 	5	  
	 2.9        Proprietary Information Agreements
	  	 	6	  
	 2.10      Patents and Trademarks
	  	 	6	  
	 2.11      Compliance with Other Instruments
	  	 	7	  
	 2.12      Agreements; Action
	  	 	7	  
	 2.13      Related-Party Transactions
	  	 	8	  
	 2.14      Permits
	  	 	8	  
	 2.15      Disclosure
	  	 	8	  
	 2.16      Registration Rights
	  	 	8	  
	 2.17      Corporate Documents
	  	 	8	  
	 2.18      Title to Property and Assets
	  	 	9	  
	 2.19      Material Liabilities
	  	 	9	  
	 2.20      Employee Benefit Plans
	  	 	9	  
	 2.21      Tax Returns
	  	 	9	  
	 2.22      Minute Books
	  	 	9	  
	 2.23      Labor Agreements and Actions; Employee Compensation
	  	 	9	  
		
	 3.      Representations and Warranties of the Investors
	  	 	10	  
	 3.1        Authorization
	  	 	10	  
	 3.2        Purchase Entirely for Own Account
	  	 	10	  
	 3.3        Disclosure of Information
	  	 	10	  
	 3.4        Investment Experience
	  	 	10	  
	 3.5        Accredited Investor
	  	 	10	  
	 3.6        Restricted Securities
	  	 	10	  
	 3.7        Further Limitations on Disposition
	  	 	11	  
	 3.8        Legends
	  	 	11	  
		
	 4.      Conditions of Investors’ Obligations at Closing
	  	 	11	  
	 4.1        Representations and Warranties
	  	 	11	  


  
 i 









					
	 4.2        Performance
	  	 	12	  
	 4.3        Compliance Certificate
	  	 	12	  
	 4.4        Qualifications
	  	 	12	  
	 4.5        Proceedings and Documents
	  	 	12	  
	 4.6        Secretary’s Certificate
	  	 	12	  
	 4.7        Payment to Shlomo Kramer
	  	 	12	  
	 4.8        Proprietary Information and Employee Stock Purchase Agreements
	  	 	12	  
	 4.9        Investors’ Rights Agreement
	  	 	12	  
	 4.10      Voting Agreement
	  	 	12	  
	 4.11      First Refusal and Co-Sale Agreement
	  	 	13	  
		
	 5.      Conditions of the Company’s Obligations at Closing
	  	 	13	  
	 5.1        Representations and Warranties
	  	 	13	  
	 5.2        Payment of Purchase Price
	  	 	13	  
	 5.3        Qualifications
	  	 	13	  
		
	 6.      Miscellaneous
	  	 	13	  
	 6.1        Survival of Warranties
	  	 	13	  
	 6.2        Successors and Assigns
	  	 	13	  
	 6.3        Governing Law
	  	 	13	  
	 6.4        Counterparts
	  	 	13	  
	 6.5        Titles and Subtitles
	  	 	13	  
	 6.6        Notices
	  	 	14	  
	 6.7        Finder’s Fee
	  	 	14	  
	 6.8        Expenses
	  	 	14	  
	 6.9        Amendments and Waivers
	  	 	14	  
	 6.10      Severability
	  	 	14	  
	 6.11      Corporate Securities Law
	  	 	15	  
	 6.12      Aggregation of Stock
	  	 	15	  
	 6.13      Entire Agreement
	  	 	15	  
	 6.14      Waiver of Conflicts
	  	 	15	  

 EXHIBIT A              Restated Certificate

 EXHIBIT B              Milestones 

EXHIBIT C              Investors’ Rights Agreement 

EXHIBIT D              Voting Agreement 

EXHIBIT E              First Refusal and Co-Sale Agreement 

SCHEDULE A        Schedule of Investors (Series A Preferred Stock) 

SCHEDULE B        Schedule of Investors (Series A-l Preferred Stock) 

  
 ii 









 INCAPSULA, INC. 

SERIES A AND SERIES A-1 PREFERRED STOCK PURCHASE AGREEMENT 

THIS SERIES A AND SERIES A-1 PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of the 9th day of March,
2010, by and among Incapsula, Inc., a Delaware corporation (the “Company”) and the investors listed on Schedule A hereto, each of which is herein referred to as an “Investor” and together, the
“Investors”. 
 WITNESSETH: 
 WHEREAS, the Company requires an infusion of funds in order to conduct its business activities; 
 WHEREAS, the Board of Directors of the Company has determined that it is in the best interests of the Company to raise capital by means of the sale and issuance to the Investors at the Closing (as
defined below) of the Series A Preferred Stock, par value $0.0001 per share (the “Series A Shares”) and the sale and issuance to the Investors at the Subsequent Closing (as defined below) of the Series A-l Preferred
Stock, par value $0.0001 per share (the “Series A-l Shares” and together with the Series A Shares, the “Shares”), on the terms and conditions more fully set forth in this Agreement; and 

WHEREAS, the Investors desire to invest in the Company pursuant to the terms and conditions more fully set forth in this
Agreement. 
 NOW, THEREFORE, the parties hereto hereby agree as follows: 

1. Purchase and Sale of Stock. 
 1.1 Sale and Issuance of Series A and Series A-l Preferred Stock. 
 (a) The Company shall adopt and file with the Secretary of State of Delaware on or before the Closing (as defined below) the Amended and Restated Certificate of Incorporation (the “Restated
Certificate”) in the form attached hereto as Exhibit A. 
 (b) On or prior to the Closing, the Company
shall have authorized (i) the sale and issuance of the Series A Shares to the Investors at the Closing, (ii) the sale and issuance of the Series A-l Shares to the Investors at the Subsequent Closing, and (iii) the issuance
of the shares of Common Stock to be issued upon conversion of the Shares (the “Conversion Shares”). The Shares and the Conversion Shares shall have the rights, preferences, privileges and restrictions set forth in the Restated
Certificate. 
 (c) Subject to the terms and conditions of this Agreement, each Investor agrees to purchase at the Closing and
the Company agrees to sell and issue to each Investor at the Closing, that number of Series A Shares set forth opposite such Investor’s name on Schedule A hereto for $0.45 per share. 







 (d) Subject to the terms and conditions of this Agreement, in the event of the Subsequent
Closing, pursuant to Section 1.3 below, each Investor agrees to purchase at the Subsequent Closing and the Company agrees to sell and issue to each Investor at the Subsequent Closing, that number of Series A-l Shares set forth opposite
such Investor’s name on Schedule B hereto for $0.80 per share. 
 1.2 Closing. The purchase and sale of
the Series A Shares shall take place at the offices of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (“Gunderson Dettmer”), 1200 Seaport Boulevard, Redwood City, California, at 11:00 A.M. (local
time), on March 9, 2010, or at such other time and place as the Company and the Investors acquiring in the aggregate a majority of the Series A Shares sold pursuant to this Agreement agree upon orally or in writing (which time and place
are designated as the “Closing”). At the Closing, the Company shall deliver to each Investor a certificate representing the Series A Shares that such Investor is purchasing pursuant to this Agreement against payment of the
purchase price therefor by check or wire transfer, or any combination thereof. 
 1.3 Subsequent Sale of Series A-l
Preferred Stock. If within eighteen (18) months of the Closing, the Company achieves those certain milestones as set forth on Exhibit B hereto (the “Milestones”), and the Chief Executive Officer of the Company
certifies in writing to each Investor that the Milestones have been achieved (the “Company CEO Certification”), then, within seven (7) days of the receipt by each Investor of the Company CEO Certification and subject to the
terms and conditions of this Agreement including the provisions contained in the following paragraph, each Investor will purchase and the Company will sell and issue at the subsequent closing (the “Subsequent Closing”) that number of
Series A-l Shares set forth opposite such Investor’s name on Schedule B hereto for $0.80 per share. Any Series A-l Shares sold pursuant to this Section 1.3 shall be deemed to be “Shares” for all purposes
under this Agreement and any purchaser thereof shall be deemed to be an “Investor” under this Agreement and each of the Ancillary Agreements (as defined below) and any amendment thereof. Where appropriate, “Closing” shall be
deemed to include a “Subsequent Closing.” Subject to the provisions contained in the following paragraph, the purchase and sale of the Series A-l Shares shall take place at the offices of Gunderson Dettmer, or at such other place as
the Company and the Investors agree upon orally or in writing, within seven (7) days of the receipt by the Investors of a written notice from the Company. At the Subsequent Closing, the Company shall deliver to each Investor a certificate
representing the Series A-l Shares that such Investor is purchasing pursuant to this Agreement against payment of the purchase price therefor by check or wire transfer, or any combination thereof. 

Notwithstanding the foregoing, the board of directors of Imperva, Inc. (the “Imperva Board”) may conduct an audit of the
Company’s achievement of the Milestones during a period of fourteen (14) days following receipt of the Company CEO Certification. In connection with such audit, the Company will provide the Imperva Board with reasonable access to the
Company’s books and records as is necessary for the Imperva Board to determine whether the Milestones have been achieved. In the event that the Imperva Board concludes that any of the Milestones have not been achieved, then the Imperva Board
shall submit to the Company a certification in writing specifying which Milestones have not been met and suggest three (3) potential independent third parties to arbitrate the dispute regarding completion of the Milestones (the “Imperva
Board Certification”). Such arbitrator shall not be an officer, director, employee, 

  
 2 








 
consultant, family member, greater than five percent (5%) stockholder or direct competitor of either Imperva or the Company. Upon the Company’s receipt of the Imperva Board
Certification, the Chief Executive Officer of the Company shall select one of the proposed arbitrators to conduct an audit to determine whether or not the Milestone(s) in question have been achieved by the Company. The Chief Executive Officer of the
Company shall provide advance notice in writing to the Imperva Board with the name of the arbitrator selected and the date the arbitrator’s audit is to commence. Prior to the commencement of the arbitrator’s audit, the arbitrator shall
enter into a nondisclosure agreement, the form of which is reasonably acceptable to the Company. The arbitrator’s audit shall be completed within twenty-eight (28) days from the commencement date of the arbitrator’s audit. If the
arbitrator determines that the Milestones in question were achieved, Imperva will bear all reasonable costs and expenses incurred by the arbitrator related to the audit. If, however, the arbitrator determines that the Milestones in question were not
achieved, all reasonable costs and expenses incurred by the arbitrator in connection with the audit will be shared by the Company. 
 2. Representations and Warranties of the Company. The Company hereby represents and warrants to each Investor that, except as set forth on a Schedule of Exceptions (the
“Schedule of Exceptions”) furnished each Investor, which exceptions shall be deemed to be representations and warranties as if made hereunder: 
 2.1 Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite
corporate power and authority to carry on its business as now conducted and as proposed to be conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a
material adverse effect on its business or properties. 
 2.2 Capitalization and Voting Rights. The authorized capital
of the Company consists, or will consist immediately prior to the Closing, of: 
 (a) Preferred Stock. Twenty Million
Four Hundred Sixteen Thousand Six Hundred Sixty-Seven (20,416,667) shares of Preferred Stock, par value $0.0001 (the “Preferred Stock”), of which, Eleven Million Six Hundred Sixty-Six Thousand Six Hundred
Sixty-Seven (11,666,667) shares were designated Series A Shares, Five Million (5,000,000) of which are outstanding and were issued by the Company to certain of the Investors pursuant to the Series A Purchase Agreement, dated
November 5, 2009, by and among the Company and certain of the Investors, and Eight Million Seven Hundred Fifty Thousand (8,750,000) shares were designated Series A-l Shares, none of which are issued and outstanding. The rights,
privileges and preferences of the Preferred Stock will be as stated in the Restated Certificate. 
 (b) Common Stock.
Thirty Million (30,000,000) shares of common stock, par value $0.0001 (the “Common Stock”), Three Million Six Hundred Thousand (3,600,000) of which are issued and outstanding, Four Million Seven Hundred and Thirty Three
Thousand Three Hundred Thirty-Three (4,733,333) of which are reserved for issuance pursuant to the Incapsula, Inc. 2010 Share Incentive Plan and Five Million (5,000,000) of which are reserved for issuance upon the conversion of the
Series A Shares. 

  
 3 








 (c) The outstanding shares of Common Stock and Preferred Stock are all duly and validly
authorized and issued, fully paid and nonassessable, and were issued in accordance with the registration or qualification provisions of the Securities Act of 1933, as amended (the “Act”), and any relevant state securities laws, or
pursuant to valid exemptions therefrom. 
 (d) Except for (i) the conversion privileges of the Shares to be issued under
this Agreement, and (ii) the rights provided in Sections 2.4, 3.1, 3.2 and 3.3 of that certain Amended and Restated Investors’ Rights Agreement in the form attached hereto as Exhibit C (the “Investors’ Rights
Agreement”), there are not outstanding any options, warrants, rights (including conversion or preemptive rights) or agreements for the purchase or acquisition from the Company of any shares of its capital stock. Other than that certain
Amended and Restated Voting Agreement in the form attached hereto as Exhibit D (the “Voting Agreement”), the Company is not a party or subject to any agreement or understanding, and, to the Company’s knowledge,
there is no agreement or understanding between any persons and/or entities, which affects or relates to the voting or giving of written consents with respect to any security or by a director of the Company. 

(e) All outstanding securities of the Company, including, without limitation, all outstanding shares of the capital stock of the
Company, all shares of the capital stock of the Company issuable upon the conversion or exercise of all convertible or exercisable securities and all other securities that the Company is obligated to issue, are subject to a one hundred
eighty (180) day “market stand-off restriction (subject to increase as requested by the Company for compliance with NASD Rule 2711) upon an initial public offering of the Company’s securities pursuant to a registration statement
filed with the Securities and Exchange Commission (“SEC”) pursuant to the Act in a form substantially identical to Section 1.13 of the Investors’ Rights Agreement. 

(f) The Schedule of Exceptions sets forth a complete list of each security of the Company owned by any officer, director or, in the
Company’s reasonable belief, key employee of the Company, or by any affiliate or any member of the immediate family of any such individual, together with a description of the material terms of the vesting provisions and, to the Company’s
knowledge, the rights of first refusal and rights of repurchase applicable to each such security. No stock plan, stock purchase, stock option or other agreement or understanding between the Company and any holder of any securities or rights
exercisable or convertible for securities provides for acceleration or other changes in the vesting provisions or other terms of such agreement or understanding as the result of the occurrence of any event. 

2.3 Subsidiaries. The Company does not presently own or control, directly or indirectly, any interest in any other corporation,
association, or other business entity. The Company is not a participant in any joint venture, partnership, or similar arrangement. 
 2.4 Authorization. All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution and delivery of this Agreement, the
Investors’ Rights Agreement, the Voting Agreement and that certain Amended and Restated First Refusal and Co-Sale Agreement in the form attached hereto as Exhibit E (the “First Refusal and Co-Sale Agreement” and,
together with the Investors’ Rights Agreement and 

  
 4 








 
the Voting Agreement, the “Ancillary Agreements”), the performance of all obligations of the Company hereunder and thereunder, and the authorization, issuance (or reservation for
issuance), sale and delivery of the Shares being sold hereunder and the Conversion Shares has been taken or will be taken prior to the Closing, and this Agreement and the Ancillary Agreements constitute valid and legally binding obligations of the
Company, enforceable in accordance with their respective terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights
generally, (b) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, and (c) to the extent the indemnification provisions contained in the Investors’ Rights Agreement
may be limited by applicable federal or state securities laws. 
 2.5 Valid Issuance of Preferred and Common Stock. The
Shares being purchased by each Investor hereunder, when issued, sold and delivered in accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued, fully paid and nonassessable and will be free
of restrictions on transfer other than restrictions on transfer under this Agreement and the Ancillary Agreements, and under applicable state and federal securities laws. The Conversion Shares have been duly and validly reserved for issuance and,
upon issuance in accordance with the terms of the Restated Certificate, will be duly and validly issued, fully paid and nonassessable and will be free of restrictions on transfer other than restrictions on transfer under this Agreement and the
Ancillary Agreements and under applicable state and federal securities laws. 
 2.6 Governmental Consents. No consent,
approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority on the part of the Company is required in connection with the consummation of the
transactions contemplated by this Agreement, except (a) the filing of the Restated Certificate with the Secretary of State of the State of Delaware; (b) the filing pursuant to Regulation D promulgated by the Securities and Exchange
Commission under the Act, as amended and the rules thereunder, which filing will be effected within fifteen (15) days of the sale of the Shares hereunder; (c) the filings required by applicable state “blue sky” securities laws,
rules and regulations; or (d) such other post-closing filings as may be required. 
 2.7 Offering. Subject in part
to the truth and accuracy of each Investor’s representations set forth in Section 3 of this Agreement, the offer, sale and issuance of the Shares as contemplated by this Agreement are exempt from the registration requirements of any
applicable state and federal securities laws, and neither the Company nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemption. 

2.8 Litigation. There is no action, suit, proceeding or investigation pending or, to the Company’s knowledge, currently
threatened against the Company that questions the validity of this Agreement or any Ancillary Agreement, or the right of the Company to enter into such agreements, or to consummate the transactions contemplated hereby or thereby, or that might
result, either individually or in the aggregate, in any material adverse changes in the assets, condition or affairs of the Company, financially or otherwise, or any change in the current equity ownership of the Company. The foregoing includes,
without limitation, actions, suits, proceedings or investigations pending or threatened involving the prior 

  
 5 








 
employment of any of the Company’s employees, their use in connection with the Company’s business of any information or techniques allegedly proprietary to any of their former
employers, or their obligations under any agreements with prior employers. The Company is not a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is no
action, suit, proceeding or investigation by the Company currently pending or that the Company intends to initiate. 
 2.9
Proprietary Information Agreements. Each employee and officer of the Company has executed a Proprietary Information and Inventions Agreement, and each consultant to the Company has executed a Consulting Agreement, in substantially the forms
made available to the Investors. No current or former employee has expressly excluded works or inventions or other subject matter from his or her Proprietary Information and Inventions Agreement. The Company is not aware that any of its employees,
officers or consultants are in violation thereof, and the Company will use its commercially reasonable efforts to prevent any such violation. 
 2.10 Patents and Trademarks. To its knowledge with respect to patents, trademarks, services marks and trade names only (but without having conducted any special investigation or patent or trademark
search), the Company has sufficient title and ownership of or exclusive licenses to all patents, trademarks, service marks, trade names, domain names, copyrights, trade secrets, information, proprietary rights and processes necessary for its
business as now conducted and as proposed to be conducted without any violation or infringement of, or other conflict with, the rights of others, except for such items as have yet to be conceived or developed or that are expected to be available for
licensing on reasonable terms from third parties. The Schedule of Exceptions contains a complete list of patents and pending patent applications and registrations and applications for trademarks, copyrights and domain names of, or exclusively
licensed to, the Company. There are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership of interests of any kind relating to anything referred to above in this Section 2.10 that is to any extent owned by or
exclusively licensed to the Company, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, domain names, copyrights, trade secrets, licenses,
information, proprietary rights and/or processes of any other person or entity, except, in either case, for standard end-user, object code, internal-use software license and support/maintenance agreements for software that is not and will not be
incorporated into, or used to provide or develop, the Company’s software, products or services. The Company has not received any communications alleging that the Company has violated or would violate any of the patents, trademarks, service
marks, domain names, trade names, copyrights or trade secrets or other proprietary rights of any other person or entity and the Company is not aware of any potential basis for such an allegation or of any specific reason to believe that such an
allegation may be forthcoming. The Company is not aware that any of its employees is obligated under any contract (including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any
court or administrative agency, that would interfere with the use of his or her best efforts to promote the interests of the Company or that would conflict with the Company’s business as presently conducted or as proposed to be conducted.
Neither the execution nor delivery of this Agreement or the Ancillary Agreements, nor the carrying on of the Company’s business by the employees of the Company, nor the conduct of the Company’s business as proposed, will, to the
Company’s knowledge, 

  
 6 








 
conflict with or result in a breach of the terms, conditions or provisions of, or constitute a default under, any contract, covenant or instrument under which any of such employees is now
obligated. The Company does not believe it is or will be necessary to utilize any inventions of any of its employees (or people it currently intends to hire) made prior to or outside the scope of their employment by the Company. To the extent the
Company uses any “open source” or “copyleft” software or is a party to “open” or “public source” or similar licenses, the Company is in compliance with the terms of any such licenses, any such software and
licenses are listed on the Schedule of Exceptions, and the Company is not required (and, even if it distributed its software, would not be required) under any such license to (a) make or permit any disclosure or to make available any
source code for its (or any of its licensors’) proprietary software or (b) distribute or make available any of the Company’s proprietary software or intellectual property (or to permit any such distribution or availability).

 2.11 Compliance with Other Instruments. The Company is not in violation, default, conflict or breach of any provision
of its Restated Certificate or Bylaws, or in any material respect of any instrument, judgment, order, writ, decree, privacy policy or contract to which it is a party or by which it is bound, or, to its knowledge, of any provision of any federal or
state statute, rule or regulation applicable to the Company (including, without limitation, those related to privacy, personally identifiable information or export control). The execution, delivery and performance of this Agreement and the Ancillary
Agreements, and the consummation of the transactions contemplated hereby and thereby will not result in any such violation, default, conflict or breach, nor will such consummation constitute, with or without the passage of time and giving of notice,
an event that results in (a) the creation of any lien, charge or encumbrance upon any assets of the Company or (b) the suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization, or
approval applicable to the Company, its business or operations or any of its assets or properties. 
 2.12 Agreements;
Action. 
 (a) Except for agreements explicitly contemplated hereby and by the Ancillary Agreements, there are no
agreements, understandings or proposed transactions between the Company and any of its officers, directors, affiliates, or any affiliate thereof. 
 (b) There are no agreements, understandings, instruments, contracts, proposed transactions, judgments, orders, writs or decrees to which the Company is a party or by which it is bound that may involve
(i) obligations (contingent or otherwise) of, or payments to the Company in excess of, $10,000, or (ii) any material license of any patent, copyright, trade secret or other proprietary right to or from the Company (other than (A) the
nonexclusive license of the Company’s software and products in object code form in the ordinary course of business pursuant to standard end-user agreements the form of which has been provided to the Investors or (B) the nonexclusive
license to the Company of standard, generally commercially available, “off-the-shelf third party products that are not and will not to any extent be part of, or influence development of, or require payment with respect to, any product, service
or intellectual property offering of the Company), or (iii) provisions materially restricting the development, manufacture or distribution of the Company’s products or services, or (iv) indemnification by the Company with respect to
infringements of proprietary rights or otherwise. 

  
 7 








 (c) The Company has not (i) declared or paid any dividends or authorized or made any
distribution upon or with respect to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or any other liabilities individually in excess of $10,000 or, in the case of indebtedness and/or liabilities
individually less than $10,000, in excess of $50,000 in the aggregate, (iii) made any loans or advances to any person, other than ordinary advances for travel expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or
rights, other than the sale of its inventory in the ordinary course of business. 
 (d) For the purposes of subsections
(b) and (c) above, all indebtedness, liabilities, agreements, understandings, instruments, contracts and proposed transactions involving the same person or entity (including persons or entities the Company has reason to believe are
affiliated therewith) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such subsections. 
 2.13 Related-Party Transactions. No employee, officer, or director of the Company (a “Related Party”) or member of such Related Party’s immediate family, or any corporation,
partnership or other entity in which such Related Party is an officer, director or partner, or in which such Related Party has significant ownership interests or otherwise controls, is indebted to the Company, nor is the Company indebted (or
committed to make loans or extend or guarantee credit) to any of them. To the Company’s knowledge, none of such persons has any direct or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which
the Company has a business relationship, or any firm or corporation that competes with the Company, except that employees, officers, or directors of the Company and members of such Related Party’s immediate families may own stock in publicly
traded companies that may compete with the Company. No Related Party or member of their immediate family is directly or indirectly interested in any material contract with the Company. 

2.14 Permits. The Company has all franchises, permits, licenses, and any similar authority necessary for the conduct of its
business as now being conducted by it, the lack of which could materially and adversely affect the business, properties or financial condition of the Company. The Company is not in default in any material respect under any of such franchises,
permits, licenses, or other similar authority. 
 2.15 Disclosure. The Company has fully provided each Investor with all
the information that such Investor has requested for deciding whether to purchase the Shares. No certificates made or delivered in connection with this Agreement or the Ancillary Agreements contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements herein or therein not misleading. 
 2.16 Registration Rights.
Except as provided in the Investors’ Rights Agreement, the Company has not granted or agreed to grant any registration rights, including piggyback rights, to any person or entity. 

2.17 Corporate Documents. Except for amendments necessary to satisfy the representations, warranties or conditions contained in
this Agreement (the form of which amendments has been approved by the Investors), the Restated Certificate and Bylaws of the Company are in the form previously provided to the Investors. 

  
 8 








 2.18 Title to Property and Assets. The Company owns its property and assets free and
clear of all mortgages, liens, loans and encumbrances, except such encumbrances and liens that arise in the ordinary course of business and do not materially impair the Company’s ownership or use of such property or assets. With respect to the
property and assets it leases, the Company is in compliance with such leases and, to its knowledge, holds a valid leasehold interest free of any liens, claims or encumbrances. 

2.19 Material Liabilities. The Company has no liability or obligation, absolute or contingent (individually or in the aggregate),
except (i) obligations and liabilities incurred after the date of incorporation in the ordinary course of business that are not material, individually or in the aggregate, and (ii) obligations under contracts made in the ordinary course of
business that would not be required to be reflected in financial statements prepared in accordance with generally accepted accounting principles.” 
 2.20 Employee Benefit Plans. The Company does not have any Employee Benefit Plan as defined in the Employee Retirement Income Security Act of 1974. 

2.21 Tax Returns, Payments and Elections. The Company has filed all tax returns and reports (including information returns and
reports) as required by law. These returns and reports are true and correct in all material respects except to the extent that a reserve has been reflected on the financial statements in accordance with generally accepted accounting principles. The
Company has paid all taxes and other assessments due, except those contested by it in good faith that are listed in the Schedule of Exceptions. 
 2.22 Minute Books. The minute books of the Company provided to the Investors contain a complete summary of all meetings of directors and stockholders since the time of incorporation and reflect all
transactions referred to in such minutes accurately in all material respects. 
 2.23 Labor Agreements and Actions; Employee
Compensation. The Company is not bound by or subject to (and none of its assets or properties is bound by or subject to) any written or oral, express or implied, contract, commitment or arrangement with any labor union, and no labor union has
requested or, to the Company’s knowledge, has sought to represent any of the employees, representatives or agents of the Company. There is no strike or other labor dispute involving the Company pending, or to the Company’s knowledge,
threatened, that could have a material adverse effect on the assets, properties, financial condition, operating results, or business of the Company (as such business is presently conducted and as it is proposed to be conducted), nor is the Company
aware of any labor organization activity involving its employees. The Company is not aware that any officer or key employee, or that any group of key employees, intends to terminate their employment with the Company, nor does the Company have a
present intention to terminate the employment of any of the foregoing. The employment of each officer and employee of the Company is terminable at the will of the Company. To its knowledge, the Company has complied in all material respects with all
applicable state and federal equal employment opportunity and other laws related to employment. The Company is not a party to or bound by any currently effective employment contract, deferred compensation agreement, bonus plan, incentive plan,
profit sharing plan, retirement agreement, or other employee compensation agreement. The Company is not 

  
 9 








 
obligated to pay severance or any other additional compensation upon the termination of any employee. 
 3. Representations and Warranties of the Investors. Each Investor, severally and not jointly, hereby represents and warrants that: 

3.1 Authorization. Such Investor has full power and authority to enter into this Agreement and the Ancillary Agreements, and each
such Agreement constitutes its valid and legally binding obligation, enforceable in accordance with its terms except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors’ rights generally, (b) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (c) to the extent the indemnification provisions contained in
the Investors’ Rights Agreement may be limited by applicable federal or state securities laws. 
 3.2 Purchase Entirely
for Own Account. This Agreement is made with such Investor in reliance upon such Investor’s representation to the Company, which by such Investor’s execution of this Agreement such Investor hereby confirms, that the Shares to be
received by such Investor and the Conversion Shares (collectively, the “Securities”) will be acquired for investment for such Investor’s own account, not as a nominee or agent, and not with a view to the distribution of any
part thereof, and that such Investor has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, such Investor further represents that such Investor does not have any contract,
undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Securities. 
 3.3 Disclosure of Information. Such Investor believes it has received all the information it considers necessary or appropriate for deciding whether to purchase the Shares. Such Investor further
represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Shares and the business, properties, prospects and financial condition of the Company. The
foregoing, however, does not limit or modify the representations and warranties of the Company in Section 2 of this Agreement or the right of the Investors to rely thereon. 

3.4 Investment Experience. Such Investor is an investor in securities of companies in the development stage and acknowledges that
it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Shares. If other than
an individual, Investor also represents it has not been organized for the purpose of acquiring the Shares. 
 3.5 Accredited
Investor. Such Investor is an “accredited investor” within the meaning of SEC Rule 501 of Regulation D, as presently in effect. 
 3.6 Restricted Securities. Such Investor understands that the Securities will be characterized as “restricted securities” under the federal securities laws inasmuch as they are being
acquired from the Company in a transaction not involving a public offering and that 

  
 10 









 
under such laws and applicable regulations such securities may be resold without registration under the Act, only in certain limited circumstances. In this connection, such Investor represents
that it is familiar with SEC Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Act. 
 3.7 Further Limitations on Disposition. Without in any way limiting the representations set forth above, such Investor further agrees not to make any disposition of all or any portion of the
Securities unless and until: 
 (a) There is then in effect a Registration Statement under the Act covering such proposed
disposition and such disposition is made in accordance with such Registration Statement; or 
 (b)(i) Such Investor shall
have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and (ii) if reasonably requested by the Company, such Investor shall
have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company that such disposition will not require registration of such shares under the Act. It is agreed that the Company will not require opinions of counsel for
transactions made pursuant to Rule 144 except in unusual circumstances. 
 (c) Notwithstanding the provisions of
subsections (a) and (b) above, no such registration statement or opinion of counsel shall be necessary for a transfer by such Investor to any of its affiliates or subsidiaries, if the prospective transferee agrees in all such instances in
writing to be subject to the terms hereof to the same extent as if he or she were an original party hereto. 
 3.8
Legends. It is understood that the certificates evidencing the Securities may bear one or all of the following legends: 

(a) “These securities have not been registered under the Securities Act of 1933, as amended. They may not be sold, offered for
sale, pledged or hypothecated in the absence of a registration statement in effect with respect to the securities under such Act or an opinion of counsel satisfactory to the Company that such registration is not required or unless sold pursuant to
Rule 144 of such Act.” 
 (b) Any legend required by applicable state “blue sky” securities laws, rules and
regulations. 
 4. Conditions of Investors’ Obligations at Closing. The obligations of each Investor under
subsection 1.1(c) of this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions. 
 4.1 Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall be true on and as of the Closing. 

  
 11 









 4.2 Performance. The Company shall have performed and complied with all agreements,
obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing. 
 4.3 Compliance Certificate. The President of the Company shall deliver to each Investor at the Closing a certificate stating that the conditions specified in Sections 4.1 and 4.2 have been
fulfilled. 
 4.4 Qualifications. All authorizations, approvals, or permits, if any, of any governmental authority or
regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Securities pursuant to this Agreement shall be duly obtained and effective as of the Closing. 

4.5 Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated at the
Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to the Investors, and they shall have received all such counterpart original and certified or other copies of such documents as they may reasonably
request. 
 4.6 Secretary’s Certificate. The Secretary of the Company shall deliver to each Investor at the Closing
a certificate stating that the copies of the Company’s Restated Certificate and Bylaws and Board of Director and stockholder resolutions relating to the sale of the Shares attached thereto are true and complete copies of such documents and
resolutions. 
 4.7 Payment to Shlomo Kramer. The Company shall deliver to Shlomo Kramer at the Closing, in lawful money
of the United States of America, all principal and interest due and payable as of such date pursuant to that certain Convertible Promissory Note issued by the Company to Shlomo Kramer on November 16, 2009 (the “Note”). Such payment
shall be in lieu of conversion of the Note into equity securities of the Company. Upon receipt of the amount due and payable as of such date, Shlomo Kramer will return the Note to the Company and forfeit any rights he is entitled to under the Note.

 4.8 Proprietary Information and Employee Stock Purchase Agreements. Each employee of the Company shall have entered
into a Proprietary Information and Inventions Agreement, and each consultant to the Company shall have entered into a Consulting Agreement, substantially in the form previously provided or made available to the Investors. 

4.9 Investors’ Rights Agreement. The Company and each Investor shall have entered into the Amended and Restated
Investors’ Rights Agreement in the form attached hereto as Exhibit C. 
 4.10 Voting Agreement. The
Company and each Investor shall have entered into the Amended and Restated Voting Agreement in the form attached hereto as Exhibit D. 

  
 12 









 4.11 First Refusal and Co-Sale Agreement. The Company and each Investor shall have
entered into the Amended and Restated First Refusal and Co-Sale Agreement in the form attached hereto as Exhibit E. 

5. Conditions of the Company’s Obligations at Closing. The obligations of the Company to each Investor under this Agreement
are subject to the fulfillment on or before the Closing of each of the following conditions by that Investor: 
 5.1
Representations and Warranties. The representations and warranties of the Investors contained in Section 3 shall be true on and as of the Closing with the same effect as though such representations and warranties had been made on and as
of the Closing. 
 5.2 Payment of Purchase Price. The Investor shall have delivered the purchase price specified in
Section 1.1(c). 
 5.3 Qualifications. All authorizations, approvals, or permits, if any, of any governmental
authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Securities pursuant to this Agreement shall be duly obtained and effective as of the Closing. 

6. Miscellaneous. 
 6.1 Survival of Warranties. The warranties, representations and covenants of the Company and Investors contained in or made pursuant to this Agreement shall survive the execution and delivery of
this Agreement and the Closing and shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of the Investors or the Company. 
 6.2 Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns
of the parties (including transferees of any Securities). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations,
or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 6.3 Governing
Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California. 

6.4 Counterparts. This Agreement may be executed and delivered by facsimile or electronic signature and in two (2) or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. 
 6.5 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

  
 13 









 6.6 Notices. All notices and other communications given or made pursuant hereto
shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then
on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (l)day after deposit with a nationally recognized overnight courier,
specifying next day delivery, with written verification of receipt. All communications shall be sent to the respective parties at the addresses set forth on the signature pages attached hereto (or at such other addresses as shall be specified by
notice given in accordance with this Section 6.6). 
 6.7 Finder’s Fee. Each party represents that it neither
is nor will be obligated for any finders’ fee or commission in connection with this transaction. Each Investor agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a
finders’ fee (and the costs and expenses of defending against such liability or asserted liability) for which such Investor or any of its officers, partners, employees, or representatives is responsible. 

The Company agrees to indemnify and hold harmless each Investor from any liability for any commission or compensation in the nature of a
finders’ fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 

6.8 Expenses. Irrespective of whether the Closing is effected, the Company shall pay all costs and expenses that it incurs with
respect to the negotiation, execution, delivery and performance of this Agreement. If the Closing is effected, the Company shall, at the Closing, reimburse the reasonable fees and out-of-pocket expenses of Gunderson Dettmer, special counsel for
Imperva, Inc., not to exceed $10,000. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the Ancillary Agreements or the Restated Certificate, the prevailing party shall be entitled to reasonable
attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

6.9 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be
waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders of a majority of the Conversion Shares issued or issuable upon conversion of the Shares
purchased hereunder. Notwithstanding the foregoing, the provisions of Section 1.3 may be amended and the observance of any term thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only
with the written consent of the Company and Imperva. Any amendment or waiver effected in accordance with this section shall be binding upon each holder of any securities purchased under this Agreement at the time outstanding (including securities
into which such securities are convertible), each future holder of all such securities, and the Company. 
 6.10
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement 

  
 14 









 
and the balance of this Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 

6.11 Corporate Securities Law. THE SALE OF THE SECURITIES THAT ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE
COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS
EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT. 

6.12 Aggregation of Stock. All shares of the Preferred Stock held or acquired by affiliated entities or persons shall be
aggregated together for the purpose of determining the availability of any rights under this Agreement. 
 6.13 Entire
Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties and no party shall be liable or bound to any other party in any manner by any warranties, representations, or covenants except as
specifically set forth herein or therein. 
 6.14 Waiver of Conflicts. Each party to this Agreement acknowledges that
Gunderson Dettmer, counsel for Imperva, Inc., has in the past and may continue to perform legal services for certain of the Investors in matters unrelated to the transactions described in this Agreement, including the representation of such
Investors in venture capital financings and other matters. Accordingly, each party to this Agreement hereby (a) acknowledges that they have had an opportunity to ask for information relevant to this disclosure; (b) acknowledges that
Gunderson Dettmer represented Imperva, Inc. in the transaction contemplated by this Agreement and has not represented the Company or any individual stockholder or employee of the Company in connection with such transaction; and (c) gives its
informed written consent to Gunderson Dettmer’s representation of certain of the Investors in such unrelated matters and to Gunderson Dettmer’s representation of Imperva, Inc. in connection with this Agreement and the transactions
contemplated hereby. 

  
 15 









 IN WITNESS WHEREOF, the patties have executed this Agreement as of the date first above
written. 
  

									
		 		 	COMPANY
					
		 		 	By:	 		  	 /s/ Gur Shatz

		 		 	Name:	 		  	 Gur Shatz

		 		 	Title:	 		  	 CEO & President

			
	Address:	 		 	  

		 		 	  



 SIGNATURE PAGE TO SERIES A
AND SERIES A-1 PREFERRED STOCK PURCHASE 

AGREEMENT FOR INCAPSULA, INC. 







 IN WITNESS WHEREOF, the patties have executed this Agreement as of the date first above
written. 
  

					
		 	IMPERVA, INC.:
		
		 	  

			
		 	By:	  	 /s/ Shlomo Kramer

		 	Name:	  	 Shlomo Kramer

		 	Title:	  	 CEO

		
	Address:	 	3400 Bridge Parkway, Suite 101
		 	Redwood Shores, CA 94065


 SIGNATURE PAGE TO SERIES A
AND SERIES A-1 PREFERRED STOCK PURCHASE 

AGREEMENT FOR INCAPSULA, INC. 







 SCHEDULE A 
 Schedule of Investors (Series A Preferred Stock) 
  

									
	 Investor Name &
 Address
	  	Number of Shares of
Series A Preferred
Stock	 	  	Total Purchase
Price of Shares of Series
A Preferred Stock	 
	 Imperva, Inc.

3400 Bridge Parkway

Redwood City, CA 94065
	  	 	6,666,666	  	  	$	2,999,999.70	  


  
 S-1









 SCHEDULE B 
 Schedule of Investors (Series A-1 Preferred Stock) 
  

									
	 Investor Name &

Address
	  	Number of Shares of
Series A-1 Preferred
Stock	 	  	Total Purchase
Price of Shares of Series
A-1 Preferred Stock	 
	 Imperva, Inc.

3400 Bridge Parkway

Redwood City, CA 94065
	  	 	8,750,000	  	  	$	7,000,000	  


  
 S-2